Glenmark Pharma surges on getting nod for combination of Remogliflozin and Metformin

19 Aug 2019 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs. 369.40, up by 8.30 points or 2.30% from its previous closing of Rs. 361.10 on the BSE.

The scrip opened at Rs. 362.00 and has touched a high and low of Rs. 372.25 and Rs. 360.00 respectively. So far 52443 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 711.55 on 10-Sep-2018 and a 52 week low of Rs. 356.50 on 16-Aug-2019.

Last one week high and low of the scrip stood at Rs. 435.00 and Rs. 356.50 respectively. The current market cap of the company is Rs. 10426.11 crore.

The promoters holding in the company stood at 46.58%, while Institutions and Non-Institutions held 38.72% and 14.71% respectively.

Glenmark Pharmaceuticals has received regulatory approval to market a combination of its novel, patent protected and globally?researched sodium glucose co?transporter?2 (SGLT2) inhibitor Remogliflozin etabonate (Remogliflozin) and Metformin Hydrochloride (Metformin) film coated tablets in India.

The drug is indicated in the treatment of type?2 diabetes mellitus in adults. The company will commercialize the product under the brand names ‘Remo?M’ and Remozen?M’

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharma Share Price

2016.90 30.15 (1.52%)
30-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1595.00
Dr. Reddys Lab 1218.40
Cipla 1323.95
Zydus Lifesciences 885.20
Lupin 2151.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×